Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Septerna, Inc. (NASDAQ:SEPN) have been given an average recommendation of “Moderate Buy” by the eight research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $33.8333.

A number of equities research analysts have recently issued reports on SEPN shares. Zacks Research raised shares of Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Truist Financial initiated coverage on Septerna in a report on Monday, December 15th. They set a “buy” rating and a $34.00 price target for the company. Wells Fargo & Company raised Septerna from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $18.00 to $28.00 in a research note on Friday, November 14th. Wall Street Zen cut Septerna from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 10th. Finally, JonesTrading assumed coverage on shares of Septerna in a report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 target price for the company.

Insider Activity

In other news, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total transaction of $115,880.00. Following the sale, the chief operating officer directly owned 174,209 shares in the company, valued at $5,046,834.73. This trade represents a 2.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Septerna

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its position in shares of Septerna by 86.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after acquiring an additional 1,260,409 shares in the last quarter. First Light Asset Management LLC purchased a new position in Septerna in the 4th quarter worth approximately $17,308,000. Primecap Management Co. CA bought a new position in Septerna in the 4th quarter worth approximately $15,225,000. Perceptive Advisors LLC purchased a new stake in Septerna during the 2nd quarter valued at approximately $5,723,000. Finally, VR Adviser LLC bought a new stake in shares of Septerna during the second quarter valued at approximately $5,713,000.

Septerna Trading Down 4.2%

SEPN opened at $29.02 on Friday. The company’s 50 day moving average is $26.95 and its 200 day moving average is $22.27. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -19.22 and a beta of 3.85. Septerna has a 12-month low of $4.66 and a 12-month high of $32.63.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.